Report of Independent Registered Public Accounting
Firm

To the Board of Trustees of Franklin Strategic Series and
Shareholders of Franklin Biotechnology Discovery Fund and
Franklin Natural Resources Fund

Opinions on the Financial Statements

We have audited the accompanying statements of assets and
liabilities, including the schedules of investments, of Franklin
Biotechnology Discovery Fund and Franklin Natural Resources
Fund (two of the funds constituting Franklin Strategic Series,
hereafter collectively referred to as the "Funds") as of April 30,
2023, the related statements of operations for the year ended April
30, 2023, the statements of changes in net assets for each of the
two years in the period ended April 30, 2023, including the related
notes, and the financial highlights for each of the five years in the
period ended April 30, 2023 (collectively referred to as the
"financial statements"). In our opinion, the financial statements
present fairly, in all material respects, the financial position of
each of the Funds as of April 30, 2023, the results of each of their
operations for the year then ended, the changes in each of their net
assets for each of the two years in the period ended April 30, 2023
and each of the financial highlights for each of the five years in the
period ended April 30, 2023 in conformity with accounting
principles generally accepted in the United States of America.

Basis for Opinions

These financial statements are the responsibility of the Funds'
management. Our responsibility is to express an opinion on the
Funds' financial statements based on our audits. We are a public
accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be
independent with respect to the Funds in accordance with the U.S.
federal securities laws and the applicable rules and regulations of
the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these financial statements in
accordance with the standards of the PCAOB. Those standards
require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of
material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of
material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as
well as evaluating the overall presentation of the financial
statements. Our procedures included confirmation of securities
owned as of April 30, 2023 by correspondence with the custodian,
transfer agent and brokers; when replies were not received from
brokers, we performed other auditing procedures. We believe that
our audits provide a reasonable basis for our opinions.


/s/PricewaterhouseCoopers LLP

San Francisco, California
June 16, 2023